Clinical trial
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
NCT00102141 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00102141 |
|---|---|
| Title | Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women |
| Official title | A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg) With Placebo for a Treatment Period of 8… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension, Postmenopause |
| Intervention type | Drug |
| Interventions | Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), Placebo |
| Enrollment | 750 |
| Start date | Apr 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Jan 24, 2005 |
| Last update posted | Dec 15, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: